MedTrace Logo

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

NCT04832932 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-01-26

No results posted yet for this study

Summary

During the study, members of different online and offline communities will be followed post COVID-19 vaccination.

Injection-site (local) and systemic reaction data will be assessed on vaccination day and afterwards using either web surveys or personal communication, depending on study participant preference.

Hypothesis to be tested: The safety profile and the magnitude and durability of immune responses to the COVID-19 vaccines as well as adverse reactions depend on health conditions, metabolism and microbiomes.

Conditions

  • COVID-19 Vaccines

Interventions

BIOLOGICAL

COVID-19 vaccines

Emergency-use authorized COVID-19 vaccines

Sponsors & Collaborators

  • Aurametrix

    collaborator OTHER

  • Mebo Research, Inc.

    lead OTHER

Principal Investigators

  • Irene Gabashvili, PhD · Mebo Research, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-05
Primary Completion
2023-01-05
Completion
2025-01-05
FDA Drug
Yes

Countries

  • United States
  • Georgia
  • Kenya
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04832932 on ClinicalTrials.gov